The rate of breast cancer deaths in the U.S. has dramatically declined since 1950. As of 2023, the death rate from breast cancer was **** per 100,000 population. However, cancer is a serious public health issue in the United States and is the second leading cause of death among women. Breast cancer incidence Breast cancer symptoms include lumps or thickening of the breast tissue and may include changes to the skin. Breast cancer is driven by many factors, but age is a known risk factor. Among all age groups, the highest number of invasive breast cancer cases were among those aged 60 to 69. The incidence rate of new breast cancer cases is higher in some ethnicities than others. White, non-Hispanic women have the highest incidence rate of breast cancer, followed by non-Hispanic Black women. Breast cancer treatment Breast cancer treatments usually involve several methods, including surgery, chemotherapy and biological therapy. Types of cancer diagnosed at earlier stages often require fewer treatments. A majority of early stage breast cancer cases in the U.S. receive breast conserving surgery and radiation therapy.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

In 2022, 175 females per 100,000 population were registered in England as newly diagnosed with breast cancer. This was an overall increase in comparison to the last few years' rate of registration. This statistic shows the rate of newly diagnosed female cases of breast cancer per 100,000 population in England from 1995 to 2022.

The 5-year prevalence rate of breast cancer cases in the Middle East and North Africa (MENA) was the highest in Turkey in 2022, followed by Bahrain at about 216 cases per 100,000 cases. Egypt had the highest number of breast cancer cases in the region in 2022.

Introduction

Breast Cancer Statistics: Breast cancer remains one of the most prevalent and concerning health challenges, mostly among women. It is the most common cancer diagnosed in women worldwide and the second leading cause of cancer-related deaths among women in the United States. The impact of breast cancer is significant, with millions of new cases diagnosed each year and hundreds of thousands of deaths attributed to the disease.

This article will provide critical insights into the incidence, survival rates, mortality, and disparities across different demographics, including age, race, and ethnicity. Understanding the latest statistics on breast cancer is crucial for driving progress in reducing the incidence and mortality rates, improving survival outcomes, and ultimately, finding a cure.

Deaths from breast cancer in females registered in the calendar year, directly standardized by age group, given as a rate per 100,000 registered female patients.

This dataset contains Cancer Incidence data for Breast Cancer (Late Stage^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are for females segmented by age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

Breast cancer is a disease which affects much more women than men. In England in 2022, over 50 thousand new cases of breast cancer were registered among women. The most affected age group was women aged 65 to 69 years of age with over 6.3 thousand cases reported.

BackgroundThis nationwide study examined breast cancer (BC) incidence and mortality rates in Hungary between 2011–2019, and the impact of the Covid-19 pandemic on the incidence and mortality rates in 2020 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary.MethodsOur nationwide, retrospective study included patients who were newly diagnosed with breast cancer (International Codes of Diseases ICD)-10 C50) between Jan 1, 2011 and Dec 31, 2020. Age-standardized incidence and mortality rates (ASRs) were calculated using European Standard Populations (ESP).Results7,729 to 8,233 new breast cancer cases were recorded in the NHIF database annually, and 3,550 to 4,909 all-cause deaths occurred within BC population per year during 2011-2019 period, while 2,096 to 2,223 breast cancer cause-specific death was recorded (CSO). Age-standardized incidence rates varied between 116.73 and 106.16/100,000 PYs, showing a mean annual change of -0.7% (95% CI: -1.21%–0.16%) and a total change of -5.41% (95% CI: -9.24 to -1.32). Age-standardized mortality rates varied between 26.65–24.97/100,000 PYs (mean annual change: -0.58%; 95% CI: -1.31–0.27%; p=0.101; total change: -5.98%; 95% CI: -13.36–2.66). Age-specific incidence rates significantly decreased between 2011 and 2019 in women aged 50–59, 60–69, 80–89, and ≥90 years (-8.22%, -14.28%, -9.14%, and -36.22%, respectively), while it increased in young females by 30.02% (95%CI 17,01%- 51,97%) during the same period. From 2019 to 2020 (in first COVID-19 pandemic year), breast cancer incidence nominally decreased by 12% (incidence rate ratio [RR]: 0.88; 95% CI: 0.69–1.13; 2020 vs. 2019), all-cause mortality nominally increased by 6% (RR: 1.06; 95% CI: 0.79–1.43) among breast cancer patients, and cause-specific mortality did not change (RR: 1.00; 95%CI: 0.86–1.15).ConclusionThe incidence of breast cancer significantly decreased in older age groups (≥50 years), oppositely increased among young females between 2011 and 2019, while cause-specific mortality in breast cancer patients showed a non-significant decrease. In 2020, the Covid-19 pandemic resulted in a nominal, but not statistically significant, 12% decrease in breast cancer incidence, with no significant increase in cause-specific breast cancer mortality observed during 2020.

Rate: Number of new cases of breast cancer (per 100,000) diagnosed at the regional or distant stage among females.

Definition: Age-adjusted incidence rate of invasive breast cancer per 100,000 female population.

Data Sources:

(1) NJ State Cancer Registry, Dec 31, 2015 Analytic File, using NCI SEER*Stat ver 8.2.1 (www.seer.cancer.gov/seerstat)

(2) NJ population estimates as calculated by the NCI's SEER Program, released January 2015, http://www.seer.cancer.gov/popdata/download.html.

The population of Middle Tennessee was assessed using publically available data collected in 2009 describing demographic and breast cancer-related characteristics of the population.*The value for each breast cancer risk factor was determined for each Middle Tennessee County, and counties were then ranked in numerical order from lowest to highest. The numerically ranked counties were then subdivided into quartiles, such that the three counties with the lowest risk factor values were placed in Quartile 1, and those with the highest were placed in Quartile 4. The range of risk factor values encompassed by each quartile are shown.1The percentage of the total female population in the county that is over the age of 50 years (a surrogate for menopause).2The breast cancer incidence per 100,000 women. 3Breast cancer mortality per 100,000 women.4The percentage of all breast cancers that were diagnosed at Stage IV.5The percentage of all breast cancers that were diagnosed without a prior mammographic screening.6The percentage of the female population lacking any form of health insurance.7The median household income.8The percentage of the population possessing higher than a high school level education.9The percentage of the population that is not Caucasian.

BackgroundCardiovascular disease (CVD) is the leading cause of morbidity and mortality among older postmenopausal women. The impact of postmenopausal breast cancer on CVD for older women is uncertain. We hypothesized that older postmenopausal women with breast cancer would be at a higher risk of CVD than similar aged women without breast cancer and that CVD would be a major contributor to the subsequent morbidity and mortality.MethodsIn a prospective Women’s Health Initiative study, incident CVD events and total and cause-specific death rates were compared between postmenopausal women with (n = 4,340) and without (n = 97,576) incident invasive breast cancer over 10 years post-diagnosis, stratified by 3 age groups (50–59, 60–69, and 70–79).ResultsPostmenopausal women, regardless of breast cancer diagnosis, had similar and high levels of CVD risk factors (e.g., smoking and hypertension) at baseline prior to breast cancer, which were strong predictors of CVD and total mortality over time. CVD affected mostly women age 70–79 with localized breast cancer (79% of breast cancer cases in 70–79 age group): only 17% died from breast cancer and CVD was the leading cause of death (22%) over the average 10 years follow up. Compared to age-matched women without breast cancer, women age 70–79 at diagnosis of localized breast cancer had a similar multivariate-adjusted hazard ratio (HR) of 1.01 (95% confidence interval [CI]: 0.76–1.33) for coronary heart disease, a lower risk of composite CVD (HR = 0.84, 95% CI: 0.70–1.00), and a higher risk of total mortality (HR = 1.20, 95% CI: 1.04–1.39).ConclusionCVD was a major contributor to mortality in women with localized breast cancer at age 70–79. Further studies are needed to evaluate both screening and treatment of localized breast cancer tailored to the specific health issues of older women.

Deaths from breast cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

BackgroundThe role of breast screening in breast cancer mortality declines is debated. Screening impacts cancer mortality through decreasing the number of advanced cancers with poor diagnosis, while cancer treatment works through decreasing the case-fatality rate. Hence, reductions in cancer death rates thanks to screening should directly reflect reductions in advanced cancer rates. We verified whether in breast screening trials, the observed reductions in the risk of breast cancer death could be predicted from reductions of advanced breast cancer rates.Patients and MethodsThe Greater New York Health Insurance Plan trial (HIP) is the only breast screening trial that reported stage-specific cancer fatality for the screening and for the control group separately. The Swedish Two-County trial (TCT)) reported size-specific fatalities for cancer patients in both screening and control groups. We computed predicted numbers of breast cancer deaths, from which we calculated predicted relative risks (RR) and (95% confidence intervals). The Age trial in England performed its own calculations of predicted relative risk.ResultsThe observed and predicted RR of breast cancer death were 0.72 (0.56–0.94) and 0.98 (0.77–1.24) in the HIP trial, and 0.79 (0.78–1.01) and 0.90 (0.80–1.01) in the Age trial. In the TCT, the observed RR was 0.73 (0.62–0.87), while the predicted RR was 0.89 (0.75–1.05) if overdiagnosis was assumed to be negligible and 0.83 (0.70–0.97) if extra cancers were excluded.ConclusionsIn breast screening trials, factors other than screening have contributed to reductions in the risk of breast cancer death most probably by reducing the fatality of advanced cancers in screening groups. These factors were the better management of breast cancer patients and the underreporting of breast cancer as the underlying cause of death. Breast screening trials should publish stage-specific fatalities observed in each group.

Legacy unique identifier: P00151

In 2022, the highest breast cancer incidence in women in Europe was estimated in Luxembourg with approximately 190 per 100,000 population. Belgium and Cyprus followed closely. The average breast cancer incidence across EU-27 was 147.6 per 100,00 population, in 2022. Cancer incidence in Europe In 2022, Denmark was the European country with the highest cancer incidence, with 728.5 cases per 100,000 population, followed by Ireland and Netherlands, with both around 641 cases per 100,000 people. Overall, the age-standardized incidence rate of cancer in all sites, excluding non-melanoma skin cancers, was 568.7 per 100,000 population in the whole of EU, with the most prevalent type of cancer being prostate cancer, followed by breast and colorectal cancer. Deaths from breast cancer In the same year, breast cancer also had the highest mortality rate among all types of cancers in women, standing at 34.1 deaths per 100,000 females. Cyprus had the highest mortality rate from breast cancer in all of EU with 45.1 deaths per 100,000 women. Meanwhile, the highest number of deaths due to breast cancer in the given year was reported in Germany, where approximately 20.6 thousand women lost their lives to breast cancer.

Source: Cancer Screening Database, HPA. Data by February 8, 2014. Note: 1. Follow-up rate for positive cases Number of positive cases completed follow-up / Number of positive cases. 2. Positive breast cancer cases are defined as: Breast screening results are "0, 4, 5", and screening dates are between October 1, 2012, and September 30, 2013.

BACKGROUND Comprehensive analyses of statistical data on breast cancer incidence, mortality, and associated risk factors are of great value for decision-making related to reducing the disease burden of breast cancer. METHODS: Based on data from the Annual Report of China Tumour Registry and the Global Burden of Disease (GBD), we conducted summary and trend analyses of incidence and mortality rates of breast cancer in Chinese women from 2014 to 2018 for urban and rural areas in the whole, eastern, central, and western parts of the country, and projected the incidence and mortality rates of breast cancer for 2019 in comparison with the GBD 2019 estimates. And the comparative risk assessment framework estimated risk factors contributing to breast cancer deaths and disability-adjusted life years (DALYs) from GBD. RESULTS: The Annual Report of the Chinese Tumour Registry showed that showed that the mortality rate of breast cancer declined and the incidence rate remained largely unchanged from 2014 to 2018. There was a significant increasing trend in incidence rates among urban and rural women in eastern China and rural women in central China, whereas there was a significant decreasing trend in mortality rates among rural women in China. The two data sources have some differences in their predictions of breast cancer in China in 2019. The GBD data estimated the age-standard DALYs rates of high body-mass index, high fasting plasma glucose and diet high in red meat, which are the top three risk factors attributable to breast cancer in Chinese women, to be 29.99/100,000, 13.66/100,000 and 13.44/100,000, respectively. Conclusion: The trend of breast cancer incidence and mortality rates shown in the Annual Report of China Tumour Registry indicates that China has achieved remarkable results in reducing the burden of breast cancer, but there is still a need to further improve breast cancer screening and early diagnosis and treatment, and to improve the system of primary prevention. The GBD database provides risk factors for breast cancer in the world, Asia, and China, and lays the foundation for research on effective measures to reduce the burden of breast cancer.

Introduction

Breast Cancer Statistics: Breast cancer stands as one of the most widespread and significant health challenges affecting women across the globe. As the most commonly diagnosed cancer in women, it poses a critical public health issue with far-reaching clinical and societal consequences. Each year, millions of women and a notable number of men receive a breast cancer diagnosis, confronting not only medical treatment but also emotional and financial hardships.

The global incidence of breast cancer continues to rise, fueled by factors such as an aging population, lifestyle-related risks, and improved awareness and diagnostic capabilities. Despite progress in early detection, advanced therapies, and survivorship programs, stark disparities persist between high- and low-income countries, largely due to unequal access to quality care and resources.

This section comprehensively analyses breast cancer statistics, covering incidence, mortality, survival rates, geographical variations, and economic burden. A clear understanding of these trends is vital for guiding policy decisions, resource allocation, and advancing breast cancer research and care delivery efforts.